Famotidine Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Alerts
• Clinical Trials
• Forums

LEAP-CT for Treatment of COVID-19 Patients (Master Protocol)
Conditions:   2019 Novel Coronavirus Disease;   2019 Novel Coronavirus Infection;   2019-nCoV Disease;   2019-nCoV Infection;   COVID-19 Pandemic;   COVID-19 Virus Disease;   COVID-19 Virus Infection;   Covid19;   Coronavirus Disease 2019;   SARS-CoV-2 Infection;   SARS-CoV-2 Acute  Respiratory Disease;   COVID-19 Interventions:   Drug: Famotidine;   Drug: Celecoxib;   Other: Placebo Sponsors:   Leidos Life Sciences;   United States Department of Defense Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 14, 2021 Category: Research Source Type: clinical trials

Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients (Addendum 2)
Conditions:   2019 Novel Coronavirus Disease;   2019 Novel Coronavirus Infection;   2019-nCoV Disease;   2019-nCoV Infection;   COVID-19;   COVID-19 Pandemic;   COVID-19 Virus Disease;   COVID-19 Virus Infection;   Covid19;   Coronavirus Disease 2019;   SARS-CoV2 Infection;   SARS-C oV-2 Acute Respiratory Disease Interventions:   Drug: Famotidine;   Drug: Celecoxib;   Drug: Placebo Sponsors:   Leidos Life Sciences;   United States Department of Defense Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 14, 2021 Category: Research Source Type: clinical trials

LEAP-CT for Treatment of COVID-19 Patients (Master Protocol)
Conditions:   2019 Novel Coronavirus Disease;   2019 Novel Coronavirus Infection;   2019-nCoV Disease;   2019-nCoV Infection;   COVID-19 Pandemic;   COVID-19 Virus Disease;   COVID-19 Virus Infection;   Covid19;   Coronavirus Disease 2019;   SARS-CoV-2 Infection;   SARS-CoV-2 Acute  Respiratory Disease;   COVID-19 Interventions:   Drug: Famotidine;   Drug: Celecoxib;   Other: Placebo Sponsors:   Leidos Life Sciences;   United States Department of Defense Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 14, 2021 Category: Research Source Type: clinical trials

Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients (Addendum 2)
Conditions:   2019 Novel Coronavirus Disease;   2019 Novel Coronavirus Infection;   2019-nCoV Disease;   2019-nCoV Infection;   COVID-19;   COVID-19 Pandemic;   COVID-19 Virus Disease;   COVID-19 Virus Infection;   Covid19;   Coronavirus Disease 2019;   SARS-CoV2 Infection;   SARS-C oV-2 Acute Respiratory Disease Interventions:   Drug: Famotidine;   Drug: Celecoxib;   Drug: Placebo Sponsors:   Leidos Life Sciences;   United States Department of Defense Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 14, 2021 Category: Research Source Type: clinical trials

LEAP-CT for Treatment of COVID-19 Patients (Master Protocol)
Conditions:   2019 Novel Coronavirus Disease;   2019 Novel Coronavirus Infection;   2019-nCoV Disease;   2019-nCoV Infection;   COVID-19 Pandemic;   COVID-19 Virus Disease;   COVID-19 Virus Infection;   Covid19;   Coronavirus Disease 2019;   SARS-CoV-2 Infection;   SARS-CoV-2 Acute  Respiratory Disease;   COVID-19 Interventions:   Drug: Famotidine;   Drug: Celecoxib;   Other: Placebo Sponsors:   Leidos Life Sciences;   United States Department of Defense Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 14, 2021 Category: Research Source Type: clinical trials

Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients (Addendum 2)
Conditions:   2019 Novel Coronavirus Disease;   2019 Novel Coronavirus Infection;   2019-nCoV Disease;   2019-nCoV Infection;   COVID-19;   COVID-19 Pandemic;   COVID-19 Virus Disease;   COVID-19 Virus Infection;   Covid19;   Coronavirus Disease 2019;   SARS-CoV2 Infection;   SARS-C oV-2 Acute Respiratory Disease Interventions:   Drug: Famotidine;   Drug: Celecoxib;   Drug: Placebo Sponsors:   Leidos Life Sciences;   United States Department of Defense Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 14, 2021 Category: Research Source Type: clinical trials

LEAP-CT for Treatment of COVID-19 Patients (Master Protocol)
Conditions:   2019 Novel Coronavirus Disease;   2019 Novel Coronavirus Infection;   2019-nCoV Disease;   2019-nCoV Infection;   COVID-19 Pandemic;   COVID-19 Virus Disease;   COVID-19 Virus Infection;   Covid19;   Coronavirus Disease 2019;   SARS-CoV-2 Infection;   SARS-CoV-2 Acute  Respiratory Disease;   COVID-19 Interventions:   Drug: Famotidine;   Drug: Celecoxib;   Other: Placebo Sponsors:   Leidos Life Sciences;   United States Department of Defense Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 14, 2021 Category: Research Source Type: clinical trials

Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients (Addendum 2)
Conditions:   2019 Novel Coronavirus Disease;   2019 Novel Coronavirus Infection;   2019-nCoV Disease;   2019-nCoV Infection;   COVID-19;   COVID-19 Pandemic;   COVID-19 Virus Disease;   COVID-19 Virus Infection;   Covid19;   Coronavirus Disease 2019;   SARS-CoV2 Infection;   SARS-C oV-2 Acute Respiratory Disease Interventions:   Drug: Famotidine;   Drug: Celecoxib;   Drug: Placebo Sponsors:   Leidos Life Sciences;   United States Department of Defense Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 14, 2021 Category: Research Source Type: clinical trials

LEAP-CT for Treatment of COVID-19 Patients (Master Protocol)
Conditions:   2019 Novel Coronavirus Disease;   2019 Novel Coronavirus Infection;   2019-nCoV Disease;   2019-nCoV Infection;   COVID-19 Pandemic;   COVID-19 Virus Disease;   COVID-19 Virus Infection;   Covid19;   Coronavirus Disease 2019;   SARS-CoV-2 Infection;   SARS-CoV-2 Acute  Respiratory Disease;   COVID-19 Interventions:   Drug: Famotidine;   Drug: Celecoxib;   Other: Placebo Sponsors:   Leidos Life Sciences;   United States Department of Defense Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 14, 2021 Category: Research Source Type: clinical trials

Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients (Addendum 2)
Conditions:   2019 Novel Coronavirus Disease;   2019 Novel Coronavirus Infection;   2019-nCoV Disease;   2019-nCoV Infection;   COVID-19;   COVID-19 Pandemic;   COVID-19 Virus Disease;   COVID-19 Virus Infection;   Covid19;   Coronavirus Disease 2019;   SARS-CoV2 Infection;   SARS-C oV-2 Acute Respiratory Disease Interventions:   Drug: Famotidine;   Drug: Celecoxib;   Drug: Placebo Sponsors:   Leidos Life Sciences;   United States Department of Defense Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 14, 2021 Category: Research Source Type: clinical trials

LEAP-CT for Treatment of COVID-19 Patients (Master Protocol)
Conditions:   2019 Novel Coronavirus Disease;   2019 Novel Coronavirus Infection;   2019-nCoV Disease;   2019-nCoV Infection;   COVID-19 Pandemic;   COVID-19 Virus Disease;   COVID-19 Virus Infection;   Covid19;   Coronavirus Disease 2019;   SARS-CoV-2 Infection;   SARS-CoV-2 Acute  Respiratory Disease;   COVID-19 Interventions:   Drug: Famotidine;   Drug: Celecoxib;   Other: Placebo Sponsors:   Leidos Life Sciences;   United States Department of Defense Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 14, 2021 Category: Research Source Type: clinical trials

Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients (Addendum 2)
Conditions:   2019 Novel Coronavirus Disease;   2019 Novel Coronavirus Infection;   2019-nCoV Disease;   2019-nCoV Infection;   COVID-19;   COVID-19 Pandemic;   COVID-19 Virus Disease;   COVID-19 Virus Infection;   Covid19;   Coronavirus Disease 2019;   SARS-CoV2 Infection;   SARS-C oV-2 Acute Respiratory Disease Interventions:   Drug: Famotidine;   Drug: Celecoxib;   Drug: Placebo Sponsors:   Leidos Life Sciences;   United States Department of Defense Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 14, 2021 Category: Research Source Type: clinical trials